Combination of lenalidomide with R-CHOP (R2CHOP) as an initial therapy for aggressive B-cell lymphomas: A phase I/II study.

Nowakowski, G. S.; Reeder, Craig B.; LaPlant, Betsy; Habermann, Thomas M.; Rivera, Candido E.; Macon, William R.; Inwards, David J.; Micallef, Ivana N.; Johnston, Patrick B.; Porrata, Luis F.; Ansell, Steven M.; Witzig, Thomas E.

doi:10.1200/jco.2011.29.15_suppl.8015

Cited by 9 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Examples of such include lenalidomide combined with RCHOP. Preliminary results of a Phase II study in 47 patients with DLCL or high-grade FL showed an ORR and CR of 98 and 83%, respectively, with a PFS of 73% at 12 months [42]. When compared with contemporary cohort of nongerminal center DLBCL patients treated with RCHOP alone PFS was improved in the study group at 12 months.…”

Section: Market Reviewmentioning

confidence: 96%

Emerging protein kinase inhibitors for the treatment of non-Hodgkin’s lymphoma

Jahangiri¹,

Friedberg²,

Barr³

2014

Expert Opinion on Emerging Drugs

View full text Add to dashboard Cite

PKIs will likely modify standard therapeutic paradigms in NHL. As use of these agents increases and combination studies continue, optimal use will depend on individual disease characteristics, goals of therapy as well as patient and societal costs. Future clinical trials need to be designed with appropriate end points given prolonged use in many cases of these orally administered, well tolerated compounds. Further, safeguards against cumulative and/or unique side effects need to be in place given the novel signaling pathways being targeted.

show abstract

Section: Market Reviewmentioning

confidence: 96%

Emerging protein kinase inhibitors for the treatment of non-Hodgkin’s lymphoma

Jahangiri¹,

Friedberg²,

Barr³

2014

Expert Opinion on Emerging Drugs

View full text Add to dashboard Cite

show abstract

“…Novakowski et al ont égale-ment combiné le lénalidomide (25 mg j1-j10) au rituximab et à la chimiothérapie de type CHOP pour des patients présentant un LNH BDGC en première ligne [25]. Sur les 30 premières observations, le taux de RG est de 100 %, dont 83 % de RC.…”

Section: Lénalidomideunclassified

The effect of angiogenesis inhibitors in the treatment of malignant blood disorders

Martis

Mounier

2012

Oncologie

View full text Add to dashboard Cite

“…For example, a phase I/II study has determined that lenalidomide can be safely given at a dose of 25 mg daily on days 1–10 of R-CHOP therapy, with high complete response rates observed. (51) Hopefully, these trials will incorporate analysis of gene expression-defined subgroups of patients, to determine the impact of this therapy on subsets of DLBCL.…”

Section: On the Horizonmentioning

confidence: 99%

New Strategies in Diffuse Large B-cell Lymphoma: Translating Findings from Gene Expression Analyses into Clinical Practice

Friedberg

2011

Clinical Cancer Research

View full text Add to dashboard Cite

Gene expression profiling has had a major impact on our understanding of the biology and heterogeneity of diffuse large B-cell lymphoma. Using this technology, biological subgroups of DLBCL can be identified that have unique targets for rational therapeutic intervention. This review summarizes these potential targets, and updates the progress of clinical development of exciting novel agents for the treatment of diffuse large B-cell lymphoma. Based upon these ongoing studies, it is likely that in the near future, we will utilize gene expression profiling, or an accurate surrogate, to define the best therapeutic approach for an individual patient with DLBCL.

show abstract

Combination of lenalidomide with R-CHOP (R2CHOP) as an initial therapy for aggressive B-cell lymphomas: A phase I/II study.

Cited by 9 publications

References 0 publications

Emerging protein kinase inhibitors for the treatment of non-Hodgkin’s lymphoma

Emerging protein kinase inhibitors for the treatment of non-Hodgkin’s lymphoma

The effect of angiogenesis inhibitors in the treatment of malignant blood disorders

New Strategies in Diffuse Large B-cell Lymphoma: Translating Findings from Gene Expression Analyses into Clinical Practice

Contact Info

Product

Resources

About